(Q37924893)

25 August 2017

1 reference

title

Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab (English)

1 reference

paroxysmal nocturnal hemoglobinuria

25 August 2017

1 reference

Alexander Röth

1

1 reference

PubMed ID

21883481

25 August 2017

Ulrich Dührsen

series ordinal

2

1 reference

25 August 2017

1 December 2011

1 reference

European Journal of Haematology

25 August 2017

1 reference

25 August 2017

87

1 reference

25 August 2017

6

1 reference

25 August 2017

473-479

1 reference

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

25 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Natural history of paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Paroxysmale nächtliche Hämoglobinurie (PNH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Paroxysmale Haemoglobinurie

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Molecular basis of paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Bone marrow transplants for paroxysmal nocturnal haemoglobinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Guidelines for the diagnosis and management of aplastic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Aplastic anemia: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01701.X

10.1111/J.1600-0609.2011.01701.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21883481